We found that patients with weak CD4+ cell infiltration and severe CD20+ cell infiltration belong to the group with a low risk of recurrence and the cancer in this group rarely occurs after 10 months (p = 0.0005) (Figure 4). This evidence concerns the gene CD4 and cancer.